Document 3012
 DOCN  M94A3012
 TI    Reasons for significant disruptions in the planned therapy of
       AIDS-related Kaposi's sarcoma.
 DT    9412
 AU    Toi M; Caven G; Gilden J; Myers AM; UCHSC-Denver General Hospital.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):173 (abstract no. PB0117). Unique
       Identifier : AIDSLINE ICA10/94369563
 AB    OBJECTIVE: To determine the frequency and causes for any significant
       disruption in planned treatment for AIDS-related Kaposi's Sarcoma (KS).
       METHODS: The care of the last 50 consecutive patients treated for
       AIDS-related KS from 1990 through 1993 was reviewed. A significant
       disruption in therapy was defined to be any delay in a scheduled cycle
       of chemotherapy beyond 2 weeks or repeated delays of at least 1 week. In
       addition, it was noted if the treatment for KS was discontinued due to
       the development of another AIDS-related illness. RESULTS: As of this
       writing, 43 of the 50 patients have died and 7 are alive. All patients
       are male. Thirty-eight had cutaneous manifestations of KS, 15 of whom
       had other sites involved as well, i.e., the GI tract, oral mucosa, lymph
       nodes, and the lungs. The remaining 12 had extracutaneous involvement
       only. The mean survival of all patients from the diagnosis of KS was 506
       days. Several chemotherapy regimens were used in treatment. These
       regimens were: Bleomycin alone, Bleomycin in combination with
       vincristine, and, Adriamycin, Bleomycin, and vincristine (ABV). 35
       patients (70%) had significant delays in or discontinuation of their
       planned therapy. The most common reasons for therapy disruption, were,
       either alone or in combination: severe neutropenia, 10 cases; CMV
       retinitis, 9 cases; PCP, 7 cases; fungal infections, 6 cases; and MAI, 6
       cases. Other less common causes were: AIDS dementia, CNS lymphoma, CNS
       Toxoplasmosis, AIDS wasting syndrome, neurological disorders, and
       Mycobacterium tuberculosis. DISCUSSION AND CONCLUSION: The treatment of
       AIDS-related KS was frequently disrupted as a result of either the
       development of treatment-related toxicity or the emergence of other
       AIDS-related illnesses with consequent compromise of the successful
       management of the KS.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY
       Antineoplastic Agents, Combined/*ADVERSE EFFECTS/THERAPEUTIC USE
       AIDS-Related Opportunistic Infections/ETIOLOGY/MORTALITY
       Bleomycins/ADMINISTRATION & DOSAGE/*ADVERSE EFFECTS  Follow-Up Studies
       Human  Neoplasms, Second Primary/DRUG THERAPY/MORTALITY  Sarcoma,
       Kaposi's/*DRUG THERAPY/MORTALITY  Skin Neoplasms/*DRUG THERAPY/MORTALITY
       Survival Rate  Treatment Outcome  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).